“We are pleased to welcome Professor Stief to our Scientific Advisory Board,” commented Dennis Giesing, PhD, Chief Scientific Officer of Urigen. “Given Chris’ extensive scientific and medical credentials, his addition to our board is a significant step forward as we strengthen the scientific base of Urigen.”

“I am excited to be joining Urigen’s Scientific Advisory Board. With the recent acquisition of URG201, Urigen has a strong product portfolio in the urology arena,” Dr. Stief said. “I look forward to working with the company on the development and commercialization of its pipeline of products for urological disorders.”

Dr. Stief is an internationally recognized scientist and practicing urologist; since 2004 he has been Professor and Chairman of the Department of Urology at the Klinikum der Ludwig-Maximilians-Universität München, the largest and one of the leading University urological centers in Europe. Professor Stief has published more than 200 manuscripts in peer reviewed journals and more that 50 chapters in medical textbooks.

About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen’s product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. URG201 targets male hypogonadism, which has been estimated to effect 13 million men in the Untied States. Urigen’s URG301 project targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further information, please visit Urigen’s website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings.

Urigen Pharmaceuticals, Inc.
Martin E. Shmagin
Chief Financial Officer
www.urigen.com
or
The Investor Relations Group
Adam Holdsworth, 212-825-3210
or
Rachel Colgate, 212-825-3210